Contents

Search


davunetide

Mechanism of action: - promotes microtubule stability - reduces tau phosphorylation Clinical trials: - davunetide is not effective for treatment of prgressive supranuclear palsy

General

peptide neurologic agent

Database Correlations

PUBCHEM correlations

References

  1. Boxer AL et al. Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014 Jul; 13:676 PMID: 24873720 http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70088-2/fulltext